YMAB — Y-mAbs Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $199.67m
- $132.44m
- $87.69m
Annual cashflow statement for Y-mAbs Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -119 | -55.3 | -95.6 | -21.4 | -29.7 |
| Depreciation | |||||
| Non-Cash Items | 24.3 | -40.8 | 29.2 | 13.2 | 17.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.44 | -7.28 | -10.4 | -19.7 | -3.65 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -91.2 | -103 | -75.9 | -27.2 | -15.7 |
| Capital Expenditures | -0.175 | -0.967 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -2.61 | 62 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.79 | 61 | 0 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 2 | 108 | 0.084 | 0.1 | 4.31 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -92.5 | 66.9 | -75.8 | -27.1 | -11.4 |